Latest Breaking News On - Business development licensing at novartis - Page 1 : comparemela.com

NEW YORK, July 21, 2022 /PRNewswire/ Ally Bridge Group (the "Firm") is pleased to announce Simos Simeonidis, PhD joined the Firm as Co-Chief Executive Officer and Co-Chief Investment Officer based in New York. Dr. Simeonidis is also assuming the role of Portfolio Manager for Ally Bridge Group's public equity strategy. Ally Bridge Group is a global healthcare investment manager focused on high-impact life science innovation addressing unmet medical needs. The Firm manages both private equity vehicles and a long-biased public equity strategy with specialization across the medical technology, tools and diagnostics, biopharmaceuticals and digital health subsectors. Ally Bridge Group was founded in 2013 by Frank Yu and has offices in New York and Hong Kong. In a recent letter sent to investors, Mr. Yu explained Dr. Simeonidis will partner with him in leading firmwide strategic initiatives and achieving investment objectives. Mr. Yu will remain at the Firm as Founder, Co-Chief

New yorkUnited statesBeth israel medical centerHong kongSimos simeonidisFrank yuMorgan stanleyGroup the firmHead of researchFirm as coFirm as founderBeth israel deaconess medical centerLoyola university of chicagoHarvard medical schoolSenior biotechnology analyst at royal bankProfessor tucker collins at harvard medical school